Last updated: September 4, 2026
Axicabtagene ciloleucel, marketed as Yescarta by Kite Pharma and Gilead Sciences, is the leading commercialized CD19-directed CAR-T therapy by revenue. U.S. sales increased from approximately $1.16 billion in 2022 to $1.57 billion in 2023 and about $1.61 billion in 2024. Growth has shifted from initial third-line large B-cell lymphoma use toward second-line treatment, follicular lymphoma, international expansion and higher manufacturing capacity.[1][2]
The principal commercial constraints are the one-time treatment price, referral and inpatient infrastructure, manufacturing turnaround time, treatment-related toxicity and competition from other CAR-T products and bispecific antibodies. U.S. biologic exclusivity runs through October 2029, although patent and manufacturing protections may influence competition beyond that date.
What is axicabtagene ciloleucel and how is it used?
Axicabtagene ciloleucel is an autologous CAR-T cell therapy in which a patient’s T cells are collected, genetically modified to express a CD19-directed chimeric antigen receptor, expanded and reinfused after lymphodepleting chemotherapy.
Yescarta is approved in the United States for adults with certain relapsed or refractory B-cell malignancies:
| U.S. indication |
Key FDA milestone |
| Relapsed or refractory large B-cell lymphoma after two or more systemic therapies |
October 18, 2017 |
| Second-line large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or relapses within 12 months |
April 1, 2022 |
| Relapsed or refractory follicular lymphoma after two or more lines of systemic therapy |
March 5, 2021 |
The second-line approval materially expanded the addressable population. It moved Yescarta earlier in the treatment sequence, where eligible patients are more numerous and may have better performance status than patients receiving third-line therapy.[3]
Yescarta requires leukapheresis, centralized or regional manufacturing, bridging therapy in some patients, lymphodepletion and administration at qualified treatment centers. The FDA label includes boxed warnings for cytokine release syndrome and neurologic toxicities.[3]
How much revenue does Yescarta generate?
Yescarta revenue has grown rapidly since launch, but the growth rate has moderated as the product entered a larger base and faced competition.
| Fiscal year |
Yescarta product sales |
Approximate annual growth |
| 2020 |
$563 million |
31% |
| 2021 |
$695 million |
23% |
| 2022 |
$1.16 billion |
67% |
| 2023 |
$1.57 billion |
36% |
| 2024 |
$1.61 billion |
2% |
Sources: Gilead annual reports and earnings disclosures.[1][2]
The 2022 increase reflected the second-line large B-cell lymphoma approval, expanded treatment-center access and recovery from pandemic-related procedure disruption. By 2024, Yescarta remained Gilead’s largest cell-therapy franchise asset, but reported growth was closer to mature-product levels.
Gilead reports Yescarta separately from Tecartus. Combined cell-therapy sales were approximately $2.1 billion in 2024 when Tecartus revenue is included.[2] Kite’s cell-therapy portfolio therefore remains strategically important to Gilead, even though Yescarta no longer has the growth profile of an early-stage launch product.
What is the commercial price of axicabtagene ciloleucel?
The U.S. wholesale acquisition cost for Yescarta has generally been approximately $424,000 for the product, excluding hospitalization, lymphodepletion, physician services, diagnostics and management of adverse events.[4]
Total treatment costs can exceed the product price because patients may require:
- Inpatient or intensive-care monitoring;
- Tocilizumab and corticosteroids for cytokine release syndrome;
- Treatment for neurologic toxicity;
- Bridging therapy before infusion;
- Extended follow-up and infection management;
- Reimbursement support for cellular therapy administration.
The economic model differs from chronic medicines. Yescarta produces one-time revenue per treated patient rather than recurring monthly or annual sales. Revenue growth therefore depends on patient throughput, treatment-center capacity, referral conversion, reimbursement and the expansion of eligible indications.
Medicare coverage for approved CAR-T indications has supported adoption in older patients, although site-of-care costs and hospital economics remain significant variables.[5]
When does Yescarta lose exclusivity?
The U.S. Biologics Price Competition and Innovation Act gives reference biologics 12 years of data exclusivity from first licensure. Yescarta received its initial U.S. biologics license on October 18, 2017. The statutory reference-product exclusivity period therefore extends to October 18, 2029.[3][6]
That date does not guarantee immediate biosimilar competition. A biosimilar sponsor must still obtain FDA approval, complete the relevant development program, resolve patent disputes or launch at risk, and establish manufacturing capacity for an autologous cell therapy.
| Protection type |
Yescarta position |
| U.S. reference-product biologic exclusivity |
Through October 2029 |
| U.S. small-molecule Orange Book listing |
Not applicable |
| U.S. biologic patent disclosure |
Not provided through the Orange Book |
| Biosimilar pathway |
Available under the BPCIA, subject to product and manufacturing complexity |
| Orphan-drug exclusivity |
Relevant to the original lymphoma indication, but does not replace biologic exclusivity |
| European protection |
Based on centralized marketing authorization, data exclusivity, market exclusivity and national patent rights |
What is the Orange Book status of axicabtagene ciloleucel?
Yescarta is a biologic, so its core U.S. regulatory and exclusivity information is not handled through the small-molecule Orange Book. The FDA’s Purple Book identifies licensed biological products and biosimilar relationships.[6]
The Orange Book does not provide a complete patent register for Yescarta. Patent risk must instead be assessed through U.S. Patent and Trademark Office records, FDA biologic information, litigation dockets and public company disclosures.
Relevant patent categories include:
- CAR architecture and antigen-binding domains;
- T-cell activation and costimulatory signaling elements;
- Viral-vector and gene-transfer processes;
- Cell expansion and culture conditions;
- Cryopreservation and formulation;
- Manufacturing controls and release testing;
- Treatment methods and patient-selection criteria.
The most defensible commercial conclusion is that Yescarta’s protection is layered rather than dependent on a single Orange Book-listed product patent. Manufacturing know-how and regulatory comparability may be as important as patent term for a follow-on autologous CAR-T product.
Are there biosimilar or generic risks for Yescarta?
There is no conventional generic substitution pathway for axicabtagene ciloleucel. A follow-on product would need to address the biological, cellular and manufacturing attributes of the reference product under the biosimilar framework.
As of the end of 2024, no FDA-approved biosimilar to Yescarta had entered the U.S. market.[6] The main risks are therefore medium- and long-term rather than immediate.
Why biosimilar competition is difficult
Autologous CAR-T products are manufactured from each patient’s cells. A follow-on developer must demonstrate control over:
- Cell collection and chain of identity;
- T-cell transduction;
- Vector consistency;
- Cell expansion;
- Viability and potency;
- Product release;
- Transport and cryopreservation;
- Infusion-site procedures.
The market could see competition before a classical biosimilar interchangeability decision if a rival developer obtains a separate biologic license for a CD19 CAR-T product. That product would compete clinically and commercially without being legally substitutable for Yescarta.
Which companies challenge Yescarta commercially?
Yescarta competes across two categories: other CAR-T therapies and non-cellular immunotherapies.
| Product |
Company |
Target or class |
Primary competitive position |
| Yescarta |
Kite/Gilead |
CD19 CAR-T |
Large B-cell lymphoma and follicular lymphoma |
| Kymriah |
Novartis |
CD19 CAR-T |
B-cell malignancies; earlier commercial entrant |
| Breyanzi |
Bristol Myers Squibb |
CD19 CAR-T |
Large B-cell lymphoma and additional B-cell indications |
| Tecartus |
Kite/Gilead |
CD19 CAR-T |
Mantle cell lymphoma and B-cell acute lymphoblastic leukemia |
| Carvykti |
Johnson & Johnson/Legend Biotech |
BCMA CAR-T |
Multiple myeloma |
| Abecma |
Bristol Myers Squibb/2seventy bio |
BCMA CAR-T |
Multiple myeloma |
| Lunsumio, Columvi and Epkinly |
Roche, Roche, AbbVie/Genmab |
Bispecific antibodies |
Off-the-shelf alternatives in B-cell lymphoma |
Yescarta’s strongest direct competition is Breyanzi in large B-cell lymphoma. Bispecific antibodies have a different logistical model: they are off-the-shelf products and avoid leukapheresis and individualized manufacturing. Their use can reduce demand for CAR-T in some lines of therapy, although CAR-T may retain advantages in durable response for selected patients.
How does Yescarta compare with Breyanzi and Kymriah?
Yescarta retains a scale advantage in commercial experience and treatment-center penetration. Breyanzi has expanded its indication base and benefits from Bristol Myers Squibb’s oncology infrastructure. Kymriah has a broad history in B-cell malignancies but has not matched Yescarta’s recent U.S. revenue trajectory.
| Factor |
Yescarta |
Breyanzi |
Kymriah |
| Sponsor |
Kite/Gilead |
Bristol Myers Squibb |
Novartis |
| Core target |
CD19 |
CD19 |
CD19 |
| Key adult lymphoma use |
Large B-cell lymphoma, follicular lymphoma |
Large B-cell lymphoma and related B-cell diseases |
B-cell malignancies |
| Manufacturing model |
Autologous |
Autologous |
Autologous |
| Commercial scale |
Highest among these products by reported revenue |
Expanding |
More mature |
| Main advantage |
Early launch, scale, second-line use |
Expanding label and oncology distribution |
Established global CAR-T platform |
| Main limitation |
Manufacturing and toxicity burden |
Same CAR-T infrastructure constraints |
Competition and manufacturing complexity |
Yescarta’s competitive position depends less on molecular differentiation than on treatment-center access, manufacturing reliability, referral networks, clinical outcomes, reimbursement and label breadth.
What patent litigation affects axicabtagene ciloleucel?
No public Orange Book-style patent litigation framework directly governs Yescarta. Patent disputes can arise under conventional patent law, contract law, trade-secret law or the BPCIA if a biosimilar sponsor challenges the reference product.
The principal litigation exposure is likely to involve:
- CAR construct ownership;
- Viral-vector technology;
- Cell-processing methods;
- Manufacturing claims;
- Research licenses;
- Inventorship and ownership;
- Trade secrets related to process control.
Kite has historically operated in a patent-intensive CAR-T environment. Earlier CAR-T disputes involving Kite, Juno Therapeutics and academic licensors demonstrated that construct and platform patents can create material financial exposure, but those disputes do not establish that Yescarta itself faces a current launch-blocking judgment.[7]
As of the end of 2024, the central commercial threat to Yescarta was competition from approved products and bispecific antibodies rather than a publicly established immediate biosimilar launch.
What generic launch scenarios exist for Yescarta?
Three launch scenarios are commercially plausible.
Scenario 1: No meaningful U.S. follow-on before 2029
This is the base-case scenario if manufacturing complexity, clinical development costs and uncertain reimbursement delay biosimilar investment. Yescarta would retain reference-product pricing and most of its U.S. franchise through the end of the decade.
Scenario 2: A separate CD19 CAR-T competitor expands before 2029
A rival autologous CAR-T product could take share without being a biosimilar. Breyanzi is the clearest current example. Competitive pressure would appear through contracting, physician preference and treatment-center allocation rather than automatic substitution.
Scenario 3: Biosimilar or follow-on entry after 2029
A post-exclusivity follow-on could compete on price, turnaround time or manufacturing flexibility. The first entrant may target high-volume indications such as large B-cell lymphoma, where established treatment pathways can support rapid commercial adoption.
What is the geographic coverage of Yescarta?
Yescarta is marketed in the United States and has approvals or commercial availability in major international markets, including the European Union, Japan and other jurisdictions.[8]
International sales are constrained by:
- National health-technology assessment;
- Country-specific reimbursement;
- Qualified treatment-center requirements;
- Cross-border manufacturing and logistics;
- Local hospital capacity;
- Pricing controls;
- Different eligibility criteria.
The United States remains the principal profit pool because of higher pricing and broader commercial infrastructure. Europe and Japan provide geographic diversification but generally produce lower net prices and slower patient access.
How strong is the Yescarta patent and market position?
Yescarta has a strong near-term market position but a less certain long-term moat.
| Strength |
Assessment |
| Clinical and regulatory position |
Strong, with first-line expansion into second-line lymphoma |
| Revenue base |
Strong, approximately $1.6 billion in 2024 |
| Manufacturing scale |
Strong relative to most CAR-T competitors |
| Biosimilar exposure before 2029 |
Low |
| Competitive exposure |
High and increasing |
| Pricing durability |
Moderate |
| Patent visibility |
Fragmented; requires jurisdiction-by-jurisdiction review |
| Long-term differentiation |
Moderate, because rival CD19 CAR-T and bispecific products are available |
The commercial moat is based on regulatory approvals, manufacturing scale, clinical evidence, treatment-center relationships and operational execution. Patent rights are important but do not alone determine market duration.
Key Takeaways
- Yescarta is the leading commercial CD19 CAR-T therapy by revenue.
- Sales reached approximately $1.61 billion in 2024 after rapid growth from 2022 through 2023.
- The 2022 second-line lymphoma approval was the main growth driver.
- U.S. biologic exclusivity runs through October 2029.
- Yescarta is not governed by the small-molecule Orange Book patent-listing system.
- No FDA-approved Yescarta biosimilar was marketed in the United States through the end of 2024.
- Breyanzi, Kymriah and bispecific antibodies are the principal competitive threats.
- Manufacturing capacity, treatment-center access and reimbursement are as important as patent term.
- Revenue growth is likely to depend on label expansion, international access and higher throughput rather than price increases.
- Long-term erosion risk is more likely to come first from rival CD19 therapies and bispecific antibodies than from automatic generic substitution.
FAQs About Axicabtagene Ciloleucel
What is the annual revenue of Yescarta?
Yescarta generated approximately $1.61 billion in product sales in 2024, according to Gilead’s reported financial results.[2]
Is axicabtagene ciloleucel a biosimilar?
No. Axicabtagene ciloleucel is the active cellular product in Yescarta, an original autologous CAR-T biologic.
When could a Yescarta biosimilar launch in the United States?
The earliest practical window begins after the October 18, 2029 reference-product exclusivity date, subject to FDA approval, patent disputes and manufacturing readiness.
What is the main alternative to Yescarta in lymphoma?
Breyanzi is the closest direct CAR-T competitor. Bispecific antibodies such as glofitamab and epcoritamab are important off-the-shelf alternatives.
Does Yescarta have an Orange Book patent?
No. Yescarta is a biologic, and its U.S. regulatory and exclusivity information is handled through the Purple Book and related patent records rather than through a standard Orange Book listing.
References
- Gilead Sciences, Inc. (2023). 2022 annual report.
- Gilead Sciences, Inc. (2025). 2024 annual report.
- U.S. Food and Drug Administration. (2024). Yescarta prescribing information.
- Kite Pharma, Inc. (2024). Yescarta product and access information.
- Centers for Medicare & Medicaid Services. (2024). National coverage analysis for autologous hematopoietic stem cell transplantation and CAR-T therapy.
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
- U.S. Court of Appeals for the Federal Circuit. (2020). Kite Pharma, Inc. v. Juno Therapeutics, Inc.
- European Medicines Agency. (2024). Yescarta: European public assessment report.
